Kit for detecting anemia marker as well as preparation method and application of kit
Through liquid chromatography-tandem mass spectrometry technology and lyophilization process, a kit was developed to solve the problem that the existing technology cannot detect multiple anemia markers in serum at the same time, and achieve efficient and stable detection, suitable for juvenile dysfunction Diagnosis of red blood cell anemia.
Patent Information
- Application Number
- CN202411135707.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-19
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-08-19
AI Technical Summary
The prior art cannot simultaneously detect homocysteine, 5-methyltetrahydrofolate, vitamin B12, vitamin C and methylmalonic acid in serum, and the detection method or kit has stability problems, so it is impossible to effectively diagnose Juyou. Red blood cell anemia and identification of nutrient deficiency causes.
A kit is developed using liquid chromatography-tandem mass spectrometry technology, including a series of calibrators, quality control products, internal standard products, protective agents and sample extracts. By optimizing mass spectrometry conditions, liquid phase conditions and chromatography columns, the above-mentioned detection is achieved simultaneously. Anemia markers and the optimization of the lyophilization process and stabilizer, improve the stability and storage capacity of the kit.
The simultaneous detection of homocysteine, 5-methyltetrahydrofolate, vitamin B12 and methylmalonic acid in serum was achieved, which simplified sample processing, improved detection sensitivity and accuracy, and developed a stability The strong kit can be stored for a long time and is suitable for screening and differential diagnosis of megaloblastic erythrocyte anemia.
Smart Images

Figure CN119000984A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of clinical testing and relates to a kit for detecting anemia markers and a preparation method and application thereof. Background Art
[0002] Megaloblastic anemia is mainly caused by a lack of folic acid, vitamin B12 or vitamin C in the body, and can also be caused by inherited or drug-induced DNA synthesis disorders. Folic acid deficiency will lead to a significant increase in homocysteine concentration. Therefore, the "Chinese Multidisciplinary Expert Consensus on Rational Clinical Folic Acid Supplementation" and the "US Centers for Disease Control and Prevention" recommend that homocysteine levels > 13 μmol / L be used as a non-specific indicator for determining functional folic acid deficiency. Serum methylmalonic acid (MMA) is a specific indicator of vitamin B12 deficiency, but it may be caused by renal failure. In addition, MMA levels can also be used to monitor treatment response. MMA levels remain normal when folic acid is deficient, while MMA levels increase when vitamin B12 or folic acid is deficient. Therefore, simultaneous detection of folic acid, vitamin B12 and vitamin C, homocysteine, and methylmalonic acid can not only effectively diagnose megaloblastic anemia, but also identify which nutrient deficiency causes anemia.
[0003] There have been many reports on detection methods and kits for folic acid, vitamin B12, methylmalonic acid, vitamin C, etc., but they all have problems such as the inability to detect simultaneously or harsh detection conditions. For example, the currently reported methods can detect 6 or 9 water-soluble vitamins by mass spectrometry, but it is difficult to meet clinical requirements. For example, Chinese patent CN201310744507.3 provides "a detection method for the simultaneous determination of 9 water-soluble vitamins", and the detection sample is a vitamin functional beverage, not a blood sample; Chinese patent CN202010172197.2 provides a "kit for detecting 9 water-soluble vitamins in serum by ultra-high performance liquid chromatography tandem mass spectrometry", and the detection sample is a serum sample; Chinese patent CN202111534070.1 provides "a detection method for multiple water-soluble vitamins", which detects 5-methyltetrahydrofolate and methylmalonic acid, but lacks the detection of homocysteine, vitamin B12 and vitamin C, and cannot be used as a detection method for anemia markers; Chinese patents CN202110418069.6 and CN201610165967.4 are both vitamin B12-specific detection methods, which are not compatible with the detection of other anemia markers. In addition, there are no stability reports for such detection methods or kits. Summary of the invention
[0004] The technical problem to be solved by the present invention is to provide a kit for detecting anemia markers and its preparation method and application in view of the deficiencies of the prior art. The present invention is based on liquid chromatography-tandem mass spectrometry technology, and develops a method for simultaneously detecting homocysteine, 5-methyltetrahydrofolate, vitamin B12, vitamin C, and methylmalonic acid in serum, and provides a kit with strong stability and long-term storage, which can be used as a method and detection reagent for screening and differential diagnosis of megaloblastic anemia.
[0005] In order to solve the above technical problems, the technical solution adopted by the present invention is as follows:
[0006] The present invention discloses a kit for detecting anemia markers, characterized in that:
[0007] The anemia markers are homocysteine, 5-methyltetrahydrofolate, methylmalonic acid, cyanocobalamin and ascorbic acid;
[0008] The kit comprises the following reagents:
[0009] (1) Series of Calibrators:
[0010] The series of calibration products are lyophilized products of a series of calibration product working solutions with five different concentration levels, and the series of calibration product working solutions are calibration product working solutions with five different concentration levels prepared by diluting a standard product working solution with a known concentration with a second solvent;
[0011] Among them, the five concentration levels of the calibrator working solution are:
[0012] Homocysteine, 5-methyltetrahydrofolate, methylmalonic acid, cyanocobalamin, and ascorbic acid in the calibrator S1 working solution were 700 ng / mL, 1.0 ng / mL, 20 ng / mL, 0.05 ng / mL, and 400 ng / mL, respectively;
[0013] Homocysteine, 5-methyltetrahydrofolate, methylmalonic acid, cyanocobalamin, and ascorbic acid in the calibrator S2 working solution were 1400 ng / mL, 2.0 ng / mL, 40 ng / mL, 0.1 ng / mL, and 800 ng / mL, respectively;
[0014] Homocysteine, 5-methyltetrahydrofolate, methylmalonic acid, cyanocobalamin, and ascorbic acid in the calibrator S3 working solution were 7000 ng / mL, 10 ng / mL, 200 ng / mL, 0.5 ng / mL, and 4000 ng / mL, respectively;
[0015] Homocysteine, 5-methyltetrahydrofolate, methylmalonic acid, cyanocobalamin, and ascorbic acid in the calibrator S4 working solution were 28000 ng / mL, 40 ng / mL, 800 ng / mL, 2.0 ng / mL, and 16000 ng / mL, respectively;
[0016] Homocysteine, 5-methyltetrahydrofolate, methylmalonic acid, cyanocobalamin, and ascorbic acid in the calibrator S5 working solution were 56000 ng / mL, 80 ng / mL, 1600 ng / mL, 4.0 ng / mL, and 32000 ng / mL, respectively;
[0017] (2) Series of quality control products:
[0018] The series of quality control products are freeze-dried products of a series of quality control product working solutions with two different concentration levels, and the series of quality control product working solutions are quality control product working solutions with two different concentration levels prepared by diluting a standard product working solution of known concentration with a second solvent;
[0019] Among them, the two concentration levels of the quality control working solution are:
[0020] The homocysteine, 5-methyltetrahydrofolate, methylmalonic acid, cyanocobalamin, and ascorbic acid in the quality control QC1 working solution were 3500 ng / mL, 5.0 ng / mL, 100 ng / mL, 0.25 ng / mL, and 2000 ng / mL, respectively;
[0021] The homocysteine, 5-methyltetrahydrofolate, methylmalonic acid, cyanocobalamin, and ascorbic acid in the quality control product QC2 working solution were 35000 ng / mL, 50 ng / mL, 1000 ng / mL, 2.5 ng / mL, and 20000 ng / mL, respectively;
[0022] (3) Internal standard:
[0023] The internal standard is a lyophilized product of the internal standard working solution;
[0024] The concentrations of homocysteine-d4, 5-methyltetrahydrofolate-d3, methylmalonic acid-d3, and ascorbic acid-13C6 in the internal standard working solution are 7000 ng / mL, 10 ng / mL, 200 ng / mL, and 4000 ng / mL, respectively;
[0025] (4) Protective agent: The protective agent is a lyophilized product of the protective agent working solution;
[0026] The protective agent working solution is a dithiothreitol aqueous solution, and the concentration of dithiothreitol in the solution is 5g / L;
[0027] (5) Sample extract: an aqueous solution containing metaphosphoric acid and sulfosalicylic acid, wherein the concentration of metaphosphoric acid and sulfosalicylic acid in the solution is 50 g / L;
[0028] (6) Mobile phase additive: an aqueous solution containing 50% formic acid and 0.2 mol / L ammonium acetate;
[0029] The calibrator, the quality control product, the internal standard product, and the protective agent are freeze-dried using the same freeze-drying process, and the freeze-drying process sequentially includes a pre-freezing stage, sublimation drying, and analytical drying;
[0030] The operating conditions of the pre-freezing stage are shown in Table 1:
[0031] Table 1
[0032]
[0033] The operating conditions of the sublimation drying are shown in Table 2:
[0034] Table 2
[0035]
[0036] The operating conditions of the analytical drying are shown in Table 3:
[0037] Table 3
[0038]
[0039] or,
[0040] The calibrator, the quality control product, the internal standard product, and the protective agent are freeze-dried using the same freeze-drying process, and the freeze-drying process sequentially includes a pre-freezing stage, sublimation drying, and analytical drying;
[0041] The operating conditions of the pre-freezing stage are shown in Table 4:
[0042] Table 4
[0043]
[0044] The operating conditions of the sublimation drying are shown in Table 5:
[0045] Table 5
[0046]
[0047] The operating conditions of the analytical drying are shown in Table 6:
[0048] Table 6
[0049]
[0050] Wherein, when the standard working solution is mixed with the second solvent, the proportion of the standard working solution added does not exceed 5% of the total volume.
[0051] In some embodiments, the second solvent consists of bovine serum albumin, an antioxidant, a preservative, a buffer and water; the antioxidant is isoascorbic acid; the preservative is citric acid; the buffer is PBS buffer; preferably, the second solvent consists of 0.1% to 5% bovine serum albumin, 0.05% to 2% isoascorbic acid, 0.05% to 2% citric acid, 10% 10×PBS buffer and deionized water; further preferably, the second solvent consists of 0.1% bovine serum albumin, 0.1% isoascorbic acid, 0.1% citric acid, 10% 10×PBS buffer and deionized water.
[0052] In some embodiments, the standard working solution of known concentration is prepared as follows:
[0053] Weigh homocysteine and mix it with 1N hydrochloric acid solution and water to prepare a standard stock solution with a concentration of 10000 μg / mL; weigh 5-methyltetrahydrofolate and mix it with ammonia water and water to prepare a standard stock solution with a concentration of 100 μg / mL; weigh methylmalonic acid and mix it with water to prepare a standard stock solution with a concentration of 1000 μg / mL; weigh cyanocobalamin and mix it with water to prepare a standard stock solution with a concentration of 10 μg / mL; weigh ascorbic acid and mix it with water to prepare a standard stock solution with a concentration of 10000 μg / mL;
[0054] The above-mentioned standard stock solutions are mixed and then prepared into a standard working solution with a first solvent; the concentration of homocysteine in the standard working solution is 1120 μg / mL, the concentration of 5-methyltetrahydrofolate is 1.6 μg / mL, the concentration of methylmalonic acid is 32 μg / mL, the concentration of cyanocobalamin is 0.08 μg / mL, and the concentration of ascorbic acid is 640 μg / mL.
[0055] The mass volume ratio of homocysteine to 1N hydrochloric acid aqueous solution is preferably 50 mg:20 μL.
[0056] The mass volume ratio of 5-methyltetrahydrofolate to ammonia water is preferably 1 mg:30 μL.
[0057] In some embodiments, the internal standard working solution is prepared as follows:
[0058] Weigh homocysteine-d4 and mix it with 1N hydrochloric acid solution and water to prepare an internal standard stock solution with a concentration of 1000 μg / mL; weigh 5-methyltetrahydrofolate-d3 and mix it with ammonia water and water to prepare an internal standard stock solution with a concentration of 100 μg / mL; weigh methylmalonic acid-d3 and mix it with water to prepare an internal standard stock solution with a concentration of 1000 μg / mL; weigh ascorbic acid-13C6 and mix it with water to prepare an internal standard stock solution with a concentration of 1000 μg / mL;
[0059] The above-mentioned internal standard stock solutions are mixed and then prepared into an internal standard working solution with a first solvent; the concentration of homocysteine-d4 in the internal standard working solution is 70 μg / mL, the concentration of 5-methyltetrahydrofolate-d3 is 0.1 μg / mL, the concentration of methylmalonic acid-d3 is 2.0 μg / mL, and the concentration of ascorbic acid-13C6 is 40 μg / mL;
[0060] The obtained internal standard working solution is mixed with the second solvent to prepare an internal standard product working solution.
[0061] Wherein, the mass volume ratio of homocysteine-d4 to 1N hydrochloric acid aqueous solution is preferably 1 mg:20 μL.
[0062] Wherein, the mass volume ratio of the 5-methyltetrahydrofolate-d3 to ammonia water is preferably 1 mg:30 μL.
[0063] In some embodiments, the first solvent consists of methanol, citric acid, dithiothreitol and deionized water; preferably, the first solvent consists of 10% methanol, 0.1% citric acid, 0.1% dithiothreitol and deionized water.
[0064] In some embodiments, preferably, the series of calibrators, the series of quality control products, the internal standard products, and the protective agent working solutions are lyophilized to obtain the series of calibrators, the series of quality control products, the internal standard products, and the protective agent, respectively;
[0065] The calibrator, the quality control product, the internal standard, and the protective agent are freeze-dried using the same freeze-drying process, and the freeze-drying process sequentially includes a pre-freezing stage, sublimation drying, and analytical drying; wherein the operating conditions of the pre-freezing stage are shown in Table 4; the operating conditions of the sublimation drying are shown in Table 5; and the operating conditions of the analytical drying are shown in Table 6.
[0066] The use of the above-mentioned kit in the simultaneous detection of anemia markers in serum using high performance liquid chromatography tandem mass spectrometry is also within the protection scope of the present invention.
[0067] Specifically, the anemia markers are homocysteine, 5-methyltetrahydrofolate, methylmalonic acid, cyanocobalamin and ascorbic acid;
[0068] Before the detection of anemia markers, the protective agent is redissolved with ultrapure water according to the concentration of dithiothreitol in the protective agent working solution, and then diluted 5 times with ultrapure water to obtain a protective agent-reconstituted solution;
[0069] The series of calibrators are re-dissolved with the protective agent-re-solution according to the corresponding five concentration levels of the series of calibrator working solutions, thereby obtaining a series of calibration sample solutions; the series of quality control products are re-dissolved with the protective agent-re-solution according to the corresponding two concentration levels of the series of quality control working solutions, thereby obtaining a series of quality control sample solutions; the internal standard products are re-dissolved with the protective agent-re-solution according to the concentration of each internal standard product in the internal standard working solution, thereby obtaining an internal standard sample working solution.
[0070] Specifically, the steps of detecting anemia markers in serum include:
[0071] The internal standard sample solution was added to the series of calibration sample solutions, the series of quality control sample solutions and the serum samples respectively, and the mixture was evenly mixed. Then, the sample extract solution was added, and the mixture was evenly mixed. After centrifugation, the supernatant was collected and subjected to LC-MS / MS detection.
[0072] Specifically, preferably, the step of detecting anemia markers in serum comprises:
[0073] 20 μL of internal standard sample solution was added to 100 μL of the series of calibration sample solutions, 100 μL of the series of quality control sample solutions and 100 μL of serum sample, respectively, and mixed, and then 100 μL of sample extract solution was added, mixed, centrifuged and the supernatant was taken, and the supernatant was subjected to LC-MS / MS detection.
[0074] Specifically, the chromatographic conditions for the LC-MS / MS detection are as follows:
[0075] Liquid chromatography conditions:
[0076] Chromatographic column: Fei Nuo Mei Luna omega Polar C18 chromatographic column, 100mm x 2.1mm; mobile phase A: aqueous solution containing 0.5% formic acid and 2mmol / L ammonium acetate; mobile phase B: methanol solution containing 0.5% formic acid and 2mmol / L ammonium acetate; injection volume 10μL, gradient elution, the specific elution conditions are shown in Table 7 below:
[0077] Table 7
[0078]
[0079]
[0080] Mass spectrometry conditions:
[0081] The mass spectrometer was Thermo scientific TSQ altis, the ion source was electrospray source, the scanning mode was positive and negative ion switching mode, the spray voltage was 3000 V, the cone voltage was 70 V, and the nebulizer flow rate was 60 L / h;
[0082] Wherein, the mobile phase A is prepared according to the following method: take the mobile phase additive and mix it with 100 times the volume of ultrapure water to obtain the mobile phase A;
[0083] The mobile phase B is prepared as follows: the mobile phase additive is mixed with 100 times the volume of methanol to obtain the mobile phase B.
[0084] The technical solution research and development ideas of the present invention are:
[0085] (1) Optimization of LC-MS / MS conditions
[0086] The present invention solves the problems of difficulty in separating methylmalonic acid and its isomer succinic acid, poor chromatographic retention and response, and the like by optimizing mass spectrometry conditions, liquid phase conditions and chromatographic columns, and establishes a method capable of simultaneously detecting homocysteine, folic acid, methylmalonic acid, vitamin B12 and vitamin C. Among the detection indicators, folic acid is active folic acid, i.e., 5-methyltetrahydrofolate, vitamin B12 is cyanocobalamin, and vitamin C is ascorbic acid.
[0087] (2) Optimization of pretreatment conditions
[0088] The invention solves the problem of serum sample pretreatment by optimizing the type, formula and dosage of a protein precipitant, and can treat the serum sample by a simple protein precipitation method to obtain test extracts of homocysteine, 5-methyltetrahydrofolate, cyanocobalamin, methylmalonic acid and ascorbic acid.
[0089] (3) Screening of stabilizers
[0090] The invention solves the problems of poor stability and difficult preservation of folic acid and ascorbic acid by optimizing the type and concentration of the stabilizer and designing experiments to verify the stability of homocysteine, 5-methyltetrahydrofolate, cyanocobalamin, methylmalonic acid and ascorbic acid calibrants.
[0091] (4) Development of freeze-drying process
[0092] The invention optimizes the freeze-drying process of the calibrant to obtain a freeze-dried product of the calibrant for simultaneously detecting homocysteine, 5-methyltetrahydrofolate, cyanocobalamin, methylmalonic acid and ascorbic acid, and designs an experiment to verify the storage stability and use stability of the freeze-dried product.
[0093] Beneficial effects:
[0094] (1) The water-soluble vitamin detection method, folic acid detection method, methylmalonic acid detection method, etc. in the prior art are unable to achieve the simultaneous detection of homocysteine, active folic acid, vitamin B12, methylmalonic acid and vitamin C. The present invention aims to solve this technical problem and invents a detection method for simultaneously detecting the above anemia markers.
[0095] (2) The current method for detecting vitamin B12 is relatively complicated. The present invention simplifies the sample processing of vitamin B12 and can simultaneously detect homocysteine, active folic acid, methylmalonic acid, vitamin B12, and vitamin C. These substances are jointly involved in folic acid metabolism, and simultaneous detection is very necessary.
[0096] (3) Since active folic acid, vitamin B12, homocysteine, and vitamin C have poor stability, especially vitamin C, and the current reagent components cannot preserve vitamin C for a long time, the present invention has developed a detection kit with strong stability that can be stored in a liquid state for 15 days. BRIEF DESCRIPTION OF THE DRAWINGS
[0097] The present invention will be further described in detail below in conjunction with the accompanying drawings and specific embodiments, and the above and / or other advantages of the present invention will become more clear.
[0098] Figure 1 The effect of different concentrations of formic acid as the mobile phase on the separation of methylmalonic acid and succinic acid; Figure 1 a in the figure is a liquid phase separation result diagram using mobile phase A as an aqueous solution containing 2 mM ammonium acetate and 0.1% formic acid, and mobile phase B as a methanol solution containing 2 mM ammonium acetate and 0.1% formic acid; Figure 1 b in the figure is a liquid phase separation result diagram using mobile phase A as an aqueous solution containing 2 mM ammonium acetate and 0.5% formic acid, and mobile phase B as a methanol solution containing 2 mM ammonium acetate and 0.5% formic acid.
[0099] Figure 2 The chromatograms of methylmalonic acid and succinic acid at channels 117>73 and 117>55, respectively; Figure 2 a is the chromatogram of methylmalonic acid and succinic acid at channels 117>73; Figure 2 Figure b is the chromatogram of methylmalonic acid and succinic acid at channel 117>55.
[0100] Figure 3 To investigate the effect of sulfosalicylic acid as a precipitant in precipitating serum samples on the detection of anemia markers.
[0101] Figure 4 To investigate the effect of precipitation of serum samples with trichloroacetic acid as precipitant on the detection of anemia markers.
[0102] Figure 5 This study aimed to investigate the effect of precipitating serum samples with metaphosphoric acid as a precipitant on the detection of anemia markers.
[0103] Figure 6 This is a schematic diagram of the packaging of anemia marker detection kit. DETAILED DESCRIPTION
[0104] The present invention can be better understood according to the following examples. However, it is easy for those skilled in the art to understand that the contents described in the examples are only used to illustrate the present invention, and should not and will not limit the present invention described in detail in the claims.
[0105] The experimental methods described in the following examples are conventional methods unless otherwise specified; the reagents and materials described are commercially available unless otherwise specified.
[0106] In the embodiments of the present invention, unless otherwise specified, v / v represents volume fraction, X% being X mL / 100 mL; m / v represents mass fraction, X% being X g / 100 mL.
[0107] The "sulfosalicylic acid" in the embodiments of the present invention refers to 5-sulfosalicylic acid unless otherwise specified.
[0108] In the embodiment of the present invention, Hcy is homocysteine; 5-MTHF is 5-methyltetrahydrofolate; VB12 is cyanocobalamin; MMA is methylmalonic acid; and VC is ascorbic acid.
[0109] Example 1
[0110] 1.1. Preparation of stock solution and working solution
[0111] (1) Preparation of standard stock solution:
[0112] Homocysteine stock solution: weigh 50 mg of homocysteine and place it in a 5 mL volumetric flask. Add ultrapure water and 20 μL of 1N hydrochloric acid aqueous solution, dissolve it by ultrasonication, and dilute it to the scale with ultrapure water to prepare a 10,000 μg / mL homocysteine stock solution.
[0113] 5-Methyltetrahydrofolate stock solution: Weigh 1 mg of 5-methyltetrahydrofolate into a 10 mL volumetric flask, add an appropriate amount of ultrapure water and 30 μL of ammonia water, dissolve by ultrasonication, and dilute to the mark with ultrapure water to prepare a 100 μg / mL 5-methyltetrahydrofolate stock solution.
[0114] Cyanocobalamin stock solution: weigh 1 mg of cyanocobalamin into a 100 mL volumetric flask, add ultrapure water and sonicate to dissolve, dilute to the mark with ultrapure water to prepare a 10 μg / mL cyanocobalamin stock solution.
[0115] Methylmalonic acid stock solution: weigh 5 mg of methylmalonic acid and place it in a 5 mL volumetric flask, add ultrapure water and ultrasonically dissolve it, and dilute to the scale with ultrapure water to prepare a 1000 μg / mL cyanocobalamin stock solution.
[0116] Ascorbic acid stock solution: weigh 50 mg of ascorbic acid into a 5 mL volumetric flask, add ultrapure water and sonicate to dissolve, dilute to the mark with ultrapure water to prepare a 10,000 μg / mL ascorbic acid stock solution.
[0117] (2) Preparation of standard working solution:
[0118] 560 μL of homocysteine stock solution, 80 μL of 5-methyltetrahydrofolate stock solution, 40 μL of cyanocobalamin stock solution, 160 μL of methylmalonic acid stock solution and 320 μL of ascorbic acid stock solution were mixed and placed in a 5 mL volumetric flask, and then the first solvent (containing 10% methanol (v / v), 0.1% citric acid (m / v), 0.1% dithiothreitol (m / v), and the balance was deionized water) was added, and the volume was fixed to the mark to prepare a standard working solution. The concentration of homocysteine in the standard working solution was 1120 μg / mL, the concentration of 5-methyltetrahydrofolate was 1.6 μg / mL, the concentration of methylmalonic acid was 32 μg / mL, the concentration of cyanocobalamin was 0.08 μg / mL, and the concentration of ascorbic acid was 640 μg / mL.
[0119] (3) Preparation of internal standard stock solution
[0120] Homocysteine-d4 stock solution: 1 mg of homocysteine-d4 is placed in a 1 mL volumetric flask, an appropriate amount of ultrapure water and 20 μL of 1N hydrochloric acid aqueous solution are added, ultrasonically dissolved, and the volume is adjusted to the scale with ultrapure water to prepare a 1000 μg / mL homocysteine-d4 stock solution.
[0121] 5-Methyltetrahydrofolate-d3 stock solution: 1 mg of 5-methyltetrahydrofolate-d3 was placed in a 10 mL volumetric flask, an appropriate amount of ultrapure water and 30 μL of ammonia water were added, and the solution was dissolved by ultrasonication. The volume was adjusted to the mark with ultrapure water to prepare a 100 μg / mL 5-methyltetrahydrofolate-d3 stock solution.
[0122] Methylmalonic acid-d3 stock solution: 1 mg of methylmalonic acid-d3 is placed in a 1 mL volumetric flask, an appropriate amount of ultrapure water is added, ultrasonically dissolved, and the volume is adjusted to the scale with ultrapure water to prepare a 1000 μg / mL methylmalonic acid-d3 stock solution.
[0123] Ascorbic acid-13C6 stock solution: 1 mg of ascorbic acid-13C6 was placed in a 1 mL volumetric flask, an appropriate amount of ultrapure water was added, and the solution was dissolved by ultrasonication. The volume was adjusted to the mark with ultrapure water to prepare a 1000 μg / mL ascorbic acid-13C6 stock solution.
[0124] (4) Preparation of internal standard working solution
[0125] 700 μL of homocysteine-d4 stock solution, 10 μL of 5-methyltetrahydrofolate-d3 stock solution, 20 μL of methylmalonic acid-d3 stock solution and 400 μL of ascorbic acid-13C6 stock solution were mixed and placed in a 10 mL volumetric flask, and the first solvent (containing 10% methanol (v / v), 0.1% citric acid (m / v), 0.1% dithiothreitol (m / v), and the balance was deionized water) was added to form an internal standard working solution. In the internal standard working solution, the concentration of homocysteine-d4 was 70 μg / mL, the concentration of 5-methyltetrahydrofolate-d3 was 0.1 μg / mL, the concentration of methylmalonic acid-d3 was 2.0 μg / mL, and the concentration of ascorbic acid-13C6 was 40 μg / mL.
[0126] 1.2. Optimization of mass spectrometry conditions
[0127] The standard working solution and internal standard working solution were injected into the mass spectrometer respectively to optimize the mass spectrometry method of homocysteine, 5-methyltetrahydrofolate, cyanocobalamin, methylmalonic acid and vitamin C.
[0128] The mass spectrometry conditions are as follows: the mass spectrometer is Thermo scientific TSQ altis, the ion source is an electrospray source (ESI) source, the scanning mode is a positive and negative ion switching mode, the spray voltage is 3000V, the cone voltage is 70V, and the nebulizer flow rate is 60L / h. The specific mass spectrometry detection conditions are shown in Table 1. The ion pairs of homocysteine are 136>90 and 136>56; the ion pairs of 5-methyltetrahydrofolate are 460>313 and 460>180; the ion pairs of cyanocobalamin are 678.5>359 and 678.5>147; the ion pairs of methylmalonic acid are 117>73 and 117>55; and the ion pairs of ascorbic acid are 177>95 and 177>141.
[0129] The ion pair of homocysteine-d4 is 140>94; the ion pair of 5-methyltetrahydrofolate-d3 is 463>316; the ion pair of methylmalonic acid-d3 is 120>76; the ion pair of ascorbic acid-13C6 is 183>147, and 5-methyltetrahydrofolate-d3 is used as the internal standard for cyanocobalamin. Detailed ion pair parameters are shown in Table 8.
[0130] Table 8 Ion pair parameters of anemia markers
[0131]
[0132] 1.3. Optimization of liquid chromatography conditions
[0133] The standard working solution in "1.1. Preparation of stock solution and working solution" was diluted 400 times with water to prepare an analyte test solution with a homocysteine concentration of 2.8 μg / mL, a 5-methyltetrahydrofolate concentration of 4 ng / mL, a methylmalonic acid concentration of 80 ng / mL, a cyanocobalamin concentration of 0.2 ng / mL, and an ascorbic acid concentration of 1.6 μg / mL.
[0134] Dilute the internal standard working solution in "1.1. Preparation of stock solution and working solution" 10 times with water to prepare an internal standard test solution with a homocysteine-d4 concentration of 7 μg / mL, 5-methyltetrahydrofolate-d3 of 10 ng / mL, methylmalonic acid-d3 of 0.2 μg / mL, and ascorbic acid-13C6 of 4 μg / mL.
[0135] 100 μL of the diluted analyte test solution was mixed with 20 μL of the internal standard test solution and placed in the automatic sample injector of the liquid chromatography-tandem mass spectrometer for optimization of the liquid phase conditions.
[0136] Liquid chromatography detection scheme 1:
[0137] Chromatographic conditions: The chromatographic column is the Fenome Luna omega Polar C18 column ( 100mm x2.1mm); mobile phase A was 2mM ammonium acetate aqueous solution containing 0.5% formic acid; mobile phase B was 2mM ammonium acetate methanol solution containing 0.5% formic acid; gradient elution, specific elution conditions are shown in Table 7.
[0138] Liquid chromatography detection scheme 2:
[0139] Chromatographic conditions: The chromatographic column is the Fenome Luna omega Polar C18 column ( 100mm x2.1mm); mobile phase A is 2mM ammonium acetate aqueous solution containing 0.1% formic acid; mobile phase B is 2mM ammonium acetate methanol solution containing 0.1% formic acid; gradient elution, the specific elution conditions are the same as those of liquid chromatography detection scheme 1, see Table 7.
[0140] Experimental results:
[0141] like Figure 1 As shown in Figure 2, the separation degree between methylmalonic acid and succinic acid increases with the increase of formic acid concentration; Figure 2As shown, under the detection conditions of liquid chromatography detection scheme two (mobile phase A is an aqueous solution containing 2 mM ammonium acetate and 0.1% formic acid; mobile phase B is a methanol solution containing 2 mM ammonium acetate and 0.1% formic acid), it was found that methylmalonic acid has a higher specificity than 117>73 under the ion pair of 117>55, and can achieve mass spectrometric separation with succinic acid without the need for chromatographic peak separation, that is, 117>55, and only methylmalonic acid peaks.
[0142] In summary, the chromatographic conditions in liquid chromatography detection scheme 1 were selected. In addition, 117>73 was preferably selected as the quantitative ion pair of methylmalonic acid. When 117>73 was interfered, 117>55 could be selected as the quantitative ion pair.
[0143] 1.4. Optimization of pre-treatment methods
[0144] In the present invention, the detection method of anemia markers is mass spectrometry, and the sample needs to be extracted from the serum sample before detection. Protein precipitation is a simple, convenient, and high-throughput biological sample processing method. The use of a protein precipitant can denature and precipitate the protein in the serum, release the small molecules of the analyte, and obtain the supernatant after centrifugation for liquid chromatography-tandem mass spectrometry analysis.
[0145] Protein precipitation generally uses organic solvents such as methanol, acetonitrile, etc., and inorganic salts such as zinc sulfate, etc., and acid solutions can also be used. Since the analytes in the present invention are all highly polar substances, if methanol or acetonitrile is used as a protein precipitant, the amount of the protein precipitant must reach 2 times or more of the sample volume, resulting in excessive dilution of the sample, and when using a C18 chromatographic column for analysis, there is an obvious solvent effect, resulting in the appearance of a front chromatographic peak.
[0146] Therefore, the present invention uses acid as a protein precipitant, and the volume of the acid solution is 0.5 to 2 times the volume of the sample to precipitate protein.
[0147] 1.4.1. Selection of precipitant
[0148] Fresh human serum samples were divided into 3 portions, 100 μL each, and placed in 1.5 mL centrifuge tubes. 20 μL of internal standard working solution (prepared in "1.1, Preparation of stock solution and working solution") was added to each centrifuge tube and shaken for 2 min to mix. Then, 0.25 mL of 5% w / v sulfosalicylic acid aqueous solution, 0.25 mL of 5% w / v trichloroacetic acid aqueous solution, and 0.25 mL of 5% w / v metaphosphoric acid aqueous solution were added to the 3 samples respectively, and shaken for 3 min to mix. After centrifugation, the supernatant was taken and injected into the liquid chromatography-tandem mass spectrometer for analysis. The chromatographic peaks of the analysis results are shown in Figure 2. Figure 3 , Figure 4 and Figure 5 .
[0149] from Figure 3 It can be seen that all five targets were detected when sulfosalicylic acid was used as a precipitant, but the responses of methylmalonic acid and cyanocobalamin were poorer than those when metaphosphoric acid was used as a precipitant. Figure 4 It can be seen that methylmalonic acid was not detected when trichloroacetic acid was used as a precipitant; Figure 5 It can be seen that when metaphosphoric acid is used as a precipitant, all five targets are detected with good responses, but the aqueous solution of metaphosphoric acid is unstable.
[0150] Since trichloroacetic acid causes strong ion suppression on methylmalonic acid, the chromatograms of serum treated with metaphosphoric acid and sulfosalicylic acid are better, but metaphosphoric acid is unstable after dissolution. In order to enhance the protein precipitation effect, sulfosalicylic acid and metaphosphoric acid are preferably selected as precipitants for sample treatment. More preferably, the mass concentrations of metaphosphoric acid and sulfosalicylic acid in the precipitant are both 5%.
[0151] 1.4.2. Optimization of precipitant dosage
[0152] The fresh human serum samples were divided into 3 portions, 100 μL of each portion was placed in a 1.5 mL centrifuge tube, 20 μL of the internal standard working solution (prepared in "1.1, Preparation of stock solution and working solution") was added to each centrifuge tube, and the mixture was shaken for 2 min; then 50 μL, 100 μL, and 200 μL of the precipitant (all containing 5% (w / v) metaphosphoric acid and 5% (w / v) sulfosalicylic acid, and the solvent was water) were added to the 3 samples, respectively, and the mixture was shaken for 3 min. After centrifugation, the supernatant was injected into a liquid chromatography-tandem mass spectrometer for analysis. The chromatographic detection conditions used the above-mentioned preferred detection conditions. The analysis results are shown in Table 9.
[0153] Table 9 Peak area results of analytes after treating samples with different precipitant volumes
[0154]
[0155] As can be seen from the table, according to the size of the analyte peak area, when the precipitant volume is 50μL and 100μL, the analyte sensitivity is higher. As the amount of precipitant increases, the sample will be diluted, resulting in a decrease in sensitivity. When the amount of precipitant is 50μL, although the peak area is larger, the protein precipitation effect is poor. Therefore, it is preferred that the amount of precipitant added during sample processing is 100μL.
[0156] Embodiment 2:
[0157] 1.1. Prepare the kit according to the following steps
[0158] The first solvent used in this experiment contains 10% methanol (v / v), 0.1% citric acid (m / v), 0.1% dithiothreitol (m / v), and the balance is deionized water.
[0159] (1) Preparation of standard stock solution:
[0160] Weigh an appropriate amount of homocysteine and place it in a volumetric flask, add ultrapure water and 20 μL of 1N hydrochloric acid aqueous solution, ultrasonically dissolve it, and use ultrapure water to dilute it to the scale to prepare a homocysteine stock solution; weigh an appropriate amount of 5-methyltetrahydrofolate and place it in a volumetric flask, add an appropriate amount of ultrapure water and 30 μL of ammonia water, ultrasonically dissolve it, and use ultrapure water to dilute it to the scale to prepare a 5-methyltetrahydrofolate stock solution; cyanocobalamin, methylmalonic acid and ascorbic acid are directly added to ultrapure water to dissolve, and dilute to the scale to prepare cyanocobalamin stock solution, methylmalonic acid stock solution and ascorbic acid stock solution. The preparation of standard stock solutions is detailed in Table 10.
[0161] Table 10 Preparation of standard stock solutions
[0162]
[0163] (2) Preparation of standard working solution
[0164] Take appropriate amounts of homocysteine stock solution, 5-methyltetrahydrofolate stock solution, cyanocobalamin stock solution, methylmalonic acid stock solution and ascorbic acid stock solution, mix them, and then add the first solvent to prepare a standard working solution. The preparation of the standard working solution is detailed in Table 11.
[0165] Table 11 Preparation of standard working solution
[0166]
[0167]
[0168] (3) Preparation of internal standard stock solution
[0169] Homocysteine-d4, 5-methyltetrahydrofolate-d3, methylmalonic acid-d3 and ascorbic acid-13C6 were weighed separately to prepare internal standard stock solutions. The preparation method and solvent were the same as those used in the standard stock solutions. The preparation method of the internal standard stock solutions is detailed in Table 12.
[0170] Table 12 Preparation of internal standard stock solution
[0171]
[0172] (4) Preparation of internal standard working solution
[0173] Take appropriate amounts of homocysteine-d4 stock solution, 5-methyltetrahydrofolate-d3 stock solution, methylmalonic acid-d3 stock solution and ascorbic acid-13C6 stock solution, mix them, add the first solvent, and prepare the internal standard working solution. The preparation method of the internal standard working solution is shown in Table 13.
[0174] Table 13 Preparation of internal standard working solution
[0175]
[0176] (5) Preparation of calibrators and quality control products
[0177] Bovine serum albumin, antioxidants, preservatives, etc. are mixed to form the second solvent. Different volumes of standard working solution are mixed with the second solvent to prepare calibrator S1 working solution, calibrator S2 working solution, calibrator S3 working solution, calibrator S4 working solution, calibrator S5 working solution, quality control QC1 working solution, quality control QC2 working solution. The preparation methods of calibrator working solution and quality control working solution are detailed in Table 14.
[0178] The second solvent is composed of bovine serum albumin, isoascorbic acid, citric acid, 10×PBS buffer and deionized water; the concentration of bovine serum albumin is 0.1% (w / v), the concentration of isoascorbic acid is 0.1% (w / v), the concentration of citric acid is 0.1% (w / v), the volume concentration of 10×PBS buffer is 10% (v / v), and the balance is deionized water.
[0179] Table 14 Preparation methods of calibrator working solution and quality control working solution
[0180]
[0181]
[0182] Homocysteine, 5-methyltetrahydrofolate, methylmalonic acid, cyanocobalamin, and ascorbic acid in the calibrator S1 working solution were 700 ng / mL, 1.0 ng / mL, 20 ng / mL, 0.05 ng / mL, and 400 ng / mL, respectively;
[0183] Homocysteine, 5-methyltetrahydrofolate, methylmalonic acid, cyanocobalamin, and ascorbic acid in the calibrator S2 working solution were 1400 ng / mL, 2.0 ng / mL, 40 ng / mL, 0.1 ng / mL, and 800 ng / mL, respectively;
[0184] Homocysteine, 5-methyltetrahydrofolate, methylmalonic acid, cyanocobalamin, and ascorbic acid in the calibrator S3 working solution were 7000 ng / mL, 10 ng / mL, 200 ng / mL, 0.5 ng / mL, and 4000 ng / mL, respectively;
[0185] Homocysteine, 5-methyltetrahydrofolate, methylmalonic acid, cyanocobalamin, and ascorbic acid in the calibrator S4 working solution were 28000 ng / mL, 40 ng / mL, 800 ng / mL, 2.0 ng / mL, and 16000 ng / mL, respectively;
[0186] Homocysteine, 5-methyltetrahydrofolate, methylmalonic acid, cyanocobalamin, and ascorbic acid in the calibrator S5 working solution were 56000 ng / mL, 80 ng / mL, 1600 ng / mL, 4.0 ng / mL, and 32000 ng / mL, respectively;
[0187] The homocysteine, 5-methyltetrahydrofolate, methylmalonic acid, cyanocobalamin, and ascorbic acid in the quality control QC1 working solution were 3500 ng / mL, 5.0 ng / mL, 100 ng / mL, 0.25 ng / mL, and 2000 ng / mL, respectively;
[0188] The concentrations of homocysteine, 5-methyltetrahydrofolate, methylmalonic acid, cyanocobalamin and ascorbic acid in the quality control product QC2 working solution were 35000 ng / mL, 50 ng / mL, 1000 ng / mL, 2.5 ng / mL and 20000 ng / mL, respectively.
[0189] The series of calibrator working solutions and quality control working solutions were dispensed into brown vials at 0.5 mL each, and lyophilized into powders, which were stored at -20°C to obtain calibrator S1, calibrator S2, calibrator S3, calibrator S4, calibrator S5, quality control QC1, and quality control QC2, respectively.
[0190] (6) Preparation of internal standard
[0191] The internal standard working solution prepared above is mixed with the second solvent to form an internal standard working solution component; wherein the volume ratio of the internal standard working solution to the second solvent is 1:9; wherein the second solvent consists of bovine serum albumin, isoascorbic acid, citric acid, 10×PBS buffer and deionized water; wherein the concentration of bovine serum albumin is 0.1% (w / v), the concentration of isoascorbic acid is 0.1% (w / v), the concentration of citric acid is 0.1% (w / v), the volume concentration of 10×PBS buffer is 10% (v / v), and the remainder is deionized water.
[0192] The concentrations of homocysteine-d4, 5-methyltetrahydrofolate-d3, methylmalonic acid-d3, and ascorbic acid-13C6 in the internal standard working solution were 7000 ng / mL, 10 ng / mL, 200 ng / mL, and 4000 ng / mL, respectively.
[0193] The internal standard working solution was dispensed into brown vials at a volume of 2 mL each, and freeze-dried into powder, which was then stored at -20°C to obtain the internal standard.
[0194] (7) Preparation of protective agent
[0195] Dithiothreitol is dissolved in ultrapure water to serve as a protective agent working solution, wherein the protective agent working solution is a dithiothreitol aqueous solution, and the concentration of dithiothreitol in the solution is 5 g / L.
[0196] The protective agent working solution is dispensed into brown vials at a volume of 2 mL each, and freeze-dried into powder, which is then stored at -20°C to obtain the protective agent.
[0197] (8) Preparation of sample extract
[0198] Metaphosphoric acid and sulfosalicylic acid were dissolved in deionized water as components of a sample extract; wherein, in the sample extract, the mass ratio of metaphosphoric acid to sulfosalicylic acid was 1:1, that is, the concentrations of metaphosphoric acid and sulfosalicylic acid were both 50 g / L.
[0199] The sample extract was dispensed into brown reagent bottles or HDPE plastic bottles at 20 mL each and stored at -20°C.
[0200] (9) Preparation of mobile phase additives
[0201] Formic acid and ammonium acetate were dissolved and mixed with deionized water to prepare an aqueous solution of 50% (v / v) formic acid and 0.2 mol / L ammonium acetate as a mobile phase additive.
[0202] Dispense the mobile phase additive into reagent bottles at 5 mL each and store at -20°C.
[0203] (10) Freeze-drying process
[0204] The above-mentioned series of calibration working solutions, quality control working solutions, internal standard working solutions, and protective agent working solutions are freeze-dried according to the following freeze-drying process. Among them, the series of calibration working solutions, quality control working solutions, internal standard working solutions, and protective agent working solutions are freeze-dried using the same freeze-drying process, and the freeze-drying process includes a pre-freezing stage, sublimation drying, and analytical drying in sequence; wherein the operating conditions of the pre-freezing stage are shown in Table 4; the operating conditions of the sublimation drying are shown in Table 5; and the operating conditions of the analytical drying are shown in Table 6.
[0205] (11) Assembly of the kit
[0206] The freeze-dried series of calibrators, series of quality control products, internal standards, protective agents, sample extracts and mobile phase additives are assembled and stored at -20°C for 15 days to obtain an anemia marker detection kit. The kit schematic is shown in Figure 6 .
[0207] 1.2. How to use the kit
[0208] (1) Before use, remove the kit from -20°C and return it to room temperature before removing the reagents in the kit;
[0209] (2) Redissolution of protective agent:
[0210] Dissolve the protective agent in 2 mL ultrapure water, place in a 50 mL centrifuge tube, add 8 mL ultrapure water, mix well, and prepare a protective agent-reconstituted solution for use. The concentration of dithiothreitol in the protective agent-reconstituted solution is 1 g / L (i.e., 0.1% (m / v)).
[0211] (3) Reconstitution of calibrators, controls and internal standards:
[0212] Add 0.5 mL of protective agent-reconstitution solution to the series of calibrators and quality control products respectively; add 2 mL of protective agent-reconstitution solution to the internal standard, shake for 30 seconds to mix, and set aside.
[0213] After reconstitution:
[0214] Homocysteine, 5-methyltetrahydrofolate, methylmalonic acid, cyanocobalamin, and ascorbic acid in calibration sample S1 were 700 ng / mL, 1.0 ng / mL, 20 ng / mL, 0.05 ng / mL, and 400 ng / mL, respectively;
[0215] Homocysteine, 5-methyltetrahydrofolate, methylmalonic acid, cyanocobalamin, and ascorbic acid in calibration sample S2 were 1400 ng / mL, 2.0 ng / mL, 40 ng / mL, 0.1 ng / mL, and 800 ng / mL, respectively;
[0216] Homocysteine, 5-methyltetrahydrofolate, methylmalonic acid, cyanocobalamin, and ascorbic acid in calibration sample S3 were 7000 ng / mL, 10 ng / mL, 200 ng / mL, 0.5 ng / mL, and 4000 ng / mL, respectively;
[0217] Homocysteine, 5-methyltetrahydrofolate, methylmalonic acid, cyanocobalamin, and ascorbic acid in calibration sample S4 were 28000 ng / mL, 40 ng / mL, 800 ng / mL, 2.0 ng / mL, and 16000 ng / mL, respectively;
[0218] Homocysteine, 5-methyltetrahydrofolate, methylmalonic acid, cyanocobalamin, and ascorbic acid in calibration sample S5 were 56000 ng / mL, 80 ng / mL, 1600 ng / mL, 4.0 ng / mL, and 32000 ng / mL, respectively;
[0219] The homocysteine, 5-methyltetrahydrofolate, methylmalonic acid, cyanocobalamin, and ascorbic acid in the quality control sample QC1 were 3500 ng / mL, 5.0 ng / mL, 100 ng / mL, 0.25 ng / mL, and 2000 ng / mL, respectively;
[0220] The homocysteine, 5-methyltetrahydrofolate, methylmalonic acid, cyanocobalamin, and ascorbic acid in the quality control sample QC2 were 35000 ng / mL, 50 ng / mL, 1000 ng / mL, 2.5 ng / mL, and 20000 ng / mL, respectively;
[0221] The concentrations of homocysteine-d4, 5-methyltetrahydrofolate-d3, methylmalonic acid-d3, and ascorbic acid-13C6 in the internal standard sample solution were 7000 ng / mL, 10 ng / mL, 200 ng / mL, and 4000 ng / mL, respectively.
[0222] (4) Preparation of mobile phase solution:
[0223] Take 2 mL of mobile phase additive (an aqueous solution containing 50% (v / v) formic acid and 0.2 mol / L ammonium acetate) and mix it with 200 mL of ultrapure water to obtain mobile phase A; mobile phase A is an aqueous solution containing 0.5% (v / v) formic acid and 2 mmol / L ammonium acetate, and is set aside.
[0224] Take 2 mL of mobile phase additive (an aqueous solution containing 50% (v / v) formic acid and 0.2 mol / L ammonium acetate) and mix it with 200 mL of methanol to obtain mobile phase B; mobile phase B is a methanol solution containing 0.5% (v / v) formic acid and 2 mmol / L ammonium acetate, and set aside.
[0225] 1.3 Sample pretreatment method
[0226] 100 μL of calibration sample S1, calibration sample S2, calibration sample S3, calibration sample S4, calibration sample S5, quality control sample QC1, quality control sample QC2, and fresh human serum were placed in 1.5 mL centrifuge tubes respectively, 20 μL of internal standard sample solution was added to each sample, vortexed for 2 min, 100 μL of sample extract was added, shaken for 3 min to mix, and the supernatant was taken after centrifugation as the sample to be tested.
[0227] 1.4. Testing conditions
[0228] Chromatographic conditions of liquid chromatography-tandem mass spectrometry:
[0229] Liquid chromatography conditions:
[0230] Mobile phase A was an aqueous solution containing 0.5% (v / v) formic acid and 2 mmol / L ammonium acetate; mobile phase B was a methanol solution containing 0.5% (v / v) formic acid and 2 mmol / L ammonium acetate; the chromatographic column was a Fenome Luna omega Polar C18 chromatographic column ( 100mm x2.1mm); injection volume 10μL, gradient elution, specific elution conditions are shown in Table 7.
[0231] Mass spectrometry conditions:
[0232] The mass spectrometer was Thermo scientific TSQ altis, the ion source was an electrospray source (ESI) source, the scanning mode was a positive and negative ion switching mode, the spray voltage was 3000 V, the cone voltage was 70 V, and the nebulizer flow rate was 60 L / h.
[0233] Among them, the ion pairs of homocysteine are 136>90 (quantitative) and 136>56 (qualitative); the ion pairs of 5-methyltetrahydrofolate are 460>313 (quantitative) and 460>180 (qualitative); the ion pairs of cyanocobalamin are 678.5>359 (quantitative) and 678.5>147 (qualitative); the ion pairs of methylmalonic acid are 117>73 (quantitative) and 117>55 (qualitative); the ion pairs of ascorbic acid are 177>95 (quantitative) and 177>141 (qualitative).
[0234] Among them, the ion pair of homocysteine-d4 is 140>94; the ion pair of 5-methyltetrahydrofolate-d3 is 463>316; the ion pair of methylmalonic acid-d3 is 120>76; the ion pair of ascorbic acid-13C6 is 183>147, and cyanocobalamin uses 5-methyltetrahydrofolate-d3 as the internal standard.
[0235] 1.5 Methodological Validation
[0236] The kit calibrator was used as the standard curve, and the quality control QC sample was used as the quality control. The performance of the anemia marker detection method of the present invention was verified by designing experiments such as quantitative limit, precision, accuracy, and linearity. The verification results are shown in Tables 15 to 31.
[0237] 1.5.1 Linear Verification
[0238] The calibration samples S1 to S5 provided with the kit were used as linearity verification samples. 1 / X fitting was used to record the correlation coefficient and slope of the linear equation. The results are shown in Table 15.
[0239] Table 15 Linearity of Analytes
[0240] Components Linear range Regression curve r Homocysteine 700~56000ng / mL y=4.80766E-5x+0.00183 0.99976 5-Methyltetrahydrofolate 1–80 ng / mL y=0.00409x+0.00111 0.99974 Methylmalonic acid 20~1600 ng / mL y=0.00356x+0.01951 0.99986 Cyanocobalamin 0.05–4 ng / mL Y=0.06111x+6.287E-4 0.99710 ascorbic acid 400~32000ng / mL Y=8.433E-5x+0.01973 0.99999
[0241] The experimental results showed that the linear equation correlation coefficients of the five anemia markers were >0.99, indicating that the detection method had a good linear relationship within the concentration range of C1 to C5.
[0242] 1.5.2 Verification of Quantitation Limit
[0243] The standard curve was used to detect samples at the quantitative lower limit concentration. Each sample was tested 5 times. The quantitative lower limit results are shown in Table 16.
[0244] Table 16 Quantitative lower limit results
[0245]
[0246]
[0247] The test results showed that at the lower limit of qualitative analysis (LLOQ) concentration, the mean deviation of the test results was <±15%, and the precision CV was <15%, which met the acceptance criteria. The quantitative limit concentration of this method can achieve accurate detection.
[0248] 1.5.3 Accuracy Verification
[0249] 1 mL of the standard working solution in Table 11 was transferred to a 5 mL volumetric flask, and the first solvent was used to dilute to the mark to obtain a standard secondary working solution. The concentrations of homocysteine, 5-methyltetrahydrofolate, methylmalonic acid, cyanocobalamin and ascorbic acid in the standard secondary working solution were 224000 ng / mL, 320 ng / mL, 6400 ng / mL, 16 ng / mL and 128000 ng / mL, respectively. 30 μL of the standard working solution and the standard secondary working solution were added to 930 μL of human serum to prepare high and low concentration recovery verification samples, which were detected using a standard curve and each concentration was measured 3 times. The recovery results are shown in Tables 17 to 21.
[0250] Table 17 Homocysteine accuracy results
[0251]
[0252] Table 18 5-Methyltetrahydrofolate accuracy results
[0253]
[0254] Table 19 Methylmalonic acid accuracy results
[0255]
[0256]
[0257] Table 20 Cyanocobalamin accuracy results
[0258]
[0259] Table 21 Ascorbic acid accuracy results
[0260]
[0261] The accuracy test results showed that the recovery rates of all indicators were in the range of 85% to 115%. The results showed that the detection method had good accuracy and met the requirements of quantitative analysis.
[0262] 1.5.4 Precision Verification
[0263] The QC samples were tested with the standard curve, and each concentration was repeated 5 times, with one analysis batch per day for three consecutive days. The statistical results of intra-batch precision and inter-batch precision are shown in Tables 22 to 26.
[0264] Table 22 Homocysteine precision results
[0265]
[0266]
[0267] Table 23 5-Methyltetrahydrofolate precision results
[0268]
[0269] Table 24 Methylmalonic acid precision results
[0270]
[0271] Table 25 Cyanocobalamin precision results
[0272]
[0273] Table 26 Ascorbic acid precision results
[0274]
[0275]
[0276] The precision verification results showed that the precision CV was less than 15%, indicating that the precision of this method met the quantitative detection requirements.
[0277] In summary, through methodological verification, it is shown that the quantitative limit, linearity, accuracy and precision of the detection method of the present invention all meet the requirements of quantitative analysis.
[0278] 1.6. Optimization of protective agent
[0279] Dithiothreitol (DTT), citric acid, and tris(2-carboxyethyl)phosphine (TCEP) were prepared into 0.1% (w / v) aqueous solutions, and 0.5 mL of each of the three protective solutions and deionized water was pipetted to dissolve the freeze-dried powder quality control product QC2 (concentration: homocysteine 35000 ng / mL, 5-methyltetrahydrofolate 50 ng / mL, methylmalonic acid 1000 ng / mL, cyanocobalamin 2.5 ng / mL, ascorbic acid 20000 ng / mL), and the samples were divided and stored in a -20°C refrigerator as samples to be tested, and were taken out for testing on the 1st day, 3rd day, 5th day, 10th day, 15th day and 30th day, respectively. The test results are shown in Tables 27 to 31.
[0280] Table 27 Stability test results of homocysteine in freeze-dried powder after different protective agent solvents
[0281]
[0282] Table 28 Stability test results of 5-sulfosalicylic acid in freeze-dried powder after different protective agent solvents
[0283]
[0284] Table 29 Stability test results of methylmalonic acid in freeze-dried powder after different protective agent solvents
[0285]
[0286] Table 30 Stability test results of cyanocobalamin in freeze-dried powder after different protective agent solvents
[0287]
[0288]
[0289] Table 31 Stability test results of ascorbic acid in lyophilized powder after different protective agent solvents
[0290]
[0291] According to the above test results, dithiothreitol is preferably used as the protective agent.
[0292] The present invention provides a kit for detecting anemia markers and its preparation method and application ideas and methods. There are many methods and ways to implement the technical solution. The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the protection scope of the present invention. All components not specified in this embodiment can be implemented by existing technologies.
Claims
1. A kit for detecting anemia markers, characterized in that: The anemia markers are homocysteine, 5-methyltetrahydrofolate, methylmalonic acid, cyanocobalamin and ascorbic acid; The kit comprises the following reagents: (1) Series of Calibrators: The series of calibration products are lyophilized products of a series of calibration product working solutions with five different concentration levels, and the series of calibration product working solutions are calibration product working solutions with five different concentration levels prepared by diluting a standard product working solution with a known concentration with a second solvent; Among them, the five concentration levels of the calibrator working solution are: Homocysteine, 5-methyltetrahydrofolate, methylmalonic acid, cyanocobalamin, and ascorbic acid in the calibrator S1 working solution were 700 ng / mL, 1.0 ng / mL, 20 ng / mL, 0.05 ng / mL, and 400 ng / mL, respectively; Homocysteine, 5-methyltetrahydrofolate, methylmalonic acid, cyanocobalamin, and ascorbic acid in the calibrator S2 working solution were 1400 ng / mL, 2.0 ng / mL, 40 ng / mL, 0.1 ng / mL, and 800 ng / mL, respectively; Homocysteine, 5-methyltetrahydrofolate, methylmalonic acid, cyanocobalamin, and ascorbic acid in the calibrator S3 working solution were 7000 ng / mL, 10 ng / mL, 200 ng / mL, 0.5 ng / mL, and 4000 ng / mL, respectively; Homocysteine, 5-methyltetrahydrofolate, methylmalonic acid, cyanocobalamin, and ascorbic acid in the calibrator S4 working solution were 28000 ng / mL, 40 ng / mL, 800 ng / mL, 2.0 ng / mL, and 16000 ng / mL, respectively; Homocysteine, 5-methyltetrahydrofolate, methylmalonic acid, cyanocobalamin, and ascorbic acid in the calibrator S5 working solution were 56000 ng / mL, 80 ng / mL, 1600 ng / mL, 4.0 ng / mL, and 32000 ng / mL, respectively; (2) Series of quality control products: The series of quality control products are freeze-dried products of a series of quality control product working solutions with two different concentration levels, and the series of quality control product working solutions are quality control product working solutions with two different concentration levels prepared by diluting a standard product working solution of known concentration with a second solvent; Among them, the two concentration levels of the quality control working solution are: The homocysteine, 5-methyltetrahydrofolate, methylmalonic acid, cyanocobalamin, and ascorbic acid in the quality control QC1 working solution were 3500 ng / mL, 5.0 ng / mL, 100 ng / mL, 0.25 ng / mL, and 2000 ng / mL, respectively; The homocysteine, 5-methyltetrahydrofolate, methylmalonic acid, cyanocobalamin, and ascorbic acid in the quality control product QC2 working solution were 35000 ng / mL, 50 ng / mL, 1000 ng / mL, 2.5 ng / mL, and 20000 ng / mL, respectively; (3) Internal standard: The internal standard is a lyophilized product of the internal standard working solution; The concentrations of homocysteine-d4, 5-methyltetrahydrofolate-d3, methylmalonic acid-d3, and ascorbic acid-13C6 in the internal standard working solution are 7000 ng / mL, 10 ng / mL, 200 ng / mL, and 4000 ng / mL, respectively; (4) Protective agent: The protective agent is a lyophilized product of the protective agent working solution; The protective agent working solution is a dithiothreitol aqueous solution, and the concentration of dithiothreitol in the solution is 5g / L; (5) Sample extract: an aqueous solution containing metaphosphoric acid and sulfosalicylic acid, wherein the concentration of metaphosphoric acid and sulfosalicylic acid in the solution is 50 g / L; (6) Mobile phase additive: an aqueous solution containing 50% formic acid and 0.2 mol / L ammonium acetate; The freeze-drying process of the calibrator, the quality control product, the internal standard product and the protective agent includes a pre-freezing stage, sublimation drying and analytical drying in sequence; The operating conditions of the pre-freezing stage are as follows: The operating conditions of the sublimation drying are as follows: The operating conditions of the analytical drying are as follows: or, The freeze-drying process of the calibrator, the quality control product, the internal standard product and the protective agent includes a pre-freezing stage, sublimation drying and analytical drying in sequence; The operating conditions of the pre-freezing stage are as follows: The operating conditions of the sublimation drying are as follows: The operating conditions of the analytical drying are as follows:
2. The kit according to claim 1, characterized in that The second solvent consists of bovine serum albumin, an antioxidant, a preservative, a buffer and water; the antioxidant is isoascorbic acid; the preservative is citric acid; the buffer is PBS buffer; preferably, the second solvent consists of 0.1% to 5% bovine serum albumin, 0.05% to 2% isoascorbic acid, 0.05% to 2% citric acid, 10% 10×PBS buffer and deionized water; further preferably, the second solvent consists of 0.1% bovine serum albumin, 0.1% isoascorbic acid, 0.1% citric acid, 10% 10×PBS buffer and deionized water.
3. The kit according to claim 1, characterized in that The standard working solution of known concentration was prepared as follows: Weigh homocysteine and mix it with 1N hydrochloric acid solution and water to prepare a standard stock solution with a concentration of 10000 μg / mL; weigh 5-methyltetrahydrofolate and mix it with ammonia water and water to prepare a standard stock solution with a concentration of 100 μg / mL; weigh methylmalonic acid and mix it with water to prepare a standard stock solution with a concentration of 1000 μg / mL; weigh cyanocobalamin and mix it with water to prepare a standard stock solution with a concentration of 10 μg / mL; weigh ascorbic acid and mix it with water to prepare a standard stock solution with a concentration of 10000 μg / mL; The above-mentioned standard stock solutions are mixed and then prepared into a standard working solution with a first solvent; the concentration of homocysteine in the standard working solution is 1120 μg / mL, the concentration of 5-methyltetrahydrofolate is 1.6 μg / mL, the concentration of methylmalonic acid is 32 μg / mL, the concentration of cyanocobalamin is 0.08 μg / mL, and the concentration of ascorbic acid is 640 μg / mL.
4. The kit according to claim 1, characterized in that The internal standard working solution is prepared as follows: Weigh homocysteine-d4 and mix it with 1N hydrochloric acid solution and water to prepare an internal standard stock solution with a concentration of 1000 μg / mL; weigh 5-methyltetrahydrofolate-d3 and mix it with ammonia water and water to prepare an internal standard stock solution with a concentration of 100 μg / mL; weigh methylmalonic acid-d3 and mix it with water to prepare an internal standard stock solution with a concentration of 1000 μg / mL; weigh ascorbic acid-13C6 and mix it with water to prepare an internal standard stock solution with a concentration of 1000 μg / mL; The above-mentioned internal standard stock solutions are mixed and then prepared into an internal standard working solution with a first solvent; the concentration of homocysteine-d4 in the internal standard working solution is 70 μg / mL, the concentration of 5-methyltetrahydrofolate-d3 is 0.1 μg / mL, the concentration of methylmalonic acid-d3 is 2.0 μg / mL, and the concentration of ascorbic acid-13C6 is 40 μg / mL; The obtained internal standard working solution is mixed with the second solvent to prepare an internal standard product working solution.
5. The kit according to claim 3 or 4, characterized in that The first solvent consists of methanol, citric acid, dithiothreitol and deionized water; preferably, the first solvent consists of 10% methanol, 0.1% citric acid, 0.1% dithiothreitol and deionized water.
6. The kit according to claim 1, characterized in that Lyophilizing the series of calibrants, the series of quality control products, the internal standard product, and the protective agent working solution, respectively, to obtain the series of calibrants, the series of quality control products, the internal standard product, and the protective agent, respectively; The freeze-drying process of the calibrator, the quality control product, the internal standard product and the protective agent includes a pre-freezing stage, sublimation drying and analytical drying in sequence; The operating conditions of the pre-freezing stage are as follows: The operating conditions of the sublimation drying are as follows: The operating conditions of the analytical drying are as follows:
7. Use of the kit according to any one of claims 1 to 6 for simultaneously detecting anemia markers in serum using high performance liquid chromatography tandem mass spectrometry.
8. The use according to claim 7, characterized in that: The anemia markers are homocysteine, 5-methyltetrahydrofolate, methylmalonic acid, cyanocobalamin and ascorbic acid; Before the detection of anemia markers, the protective agent is redissolved with ultrapure water according to the concentration of dithiothreitol in the protective agent working solution, and then diluted 5 times with ultrapure water to obtain a protective agent-reconstituted solution; The series of calibrators are re-dissolved with the protective agent-re-solution according to the corresponding five concentration levels of the series of calibrator working solutions, thereby obtaining a series of calibration sample solutions; the series of quality control products are re-dissolved with the protective agent-re-solution according to the corresponding two concentration levels of the series of quality control working solutions, thereby obtaining a series of quality control sample solutions; the internal standard products are re-dissolved with the protective agent-re-solution according to the concentration of each internal standard product in the internal standard working solution, thereby obtaining an internal standard sample working solution.
9. The use according to claim 8, characterized in that: The steps for detecting anemia markers in serum include: The internal standard sample solution was added to the series of calibration sample solutions, the series of quality control sample solutions and the serum samples respectively, and the mixture was evenly mixed. Then, the sample extract solution was added, and the mixture was evenly mixed. After centrifugation, the supernatant was collected and subjected to LC-MS / MS detection.
10. The use according to claim 9, characterized in that: The chromatographic conditions for the LC-MS / MS detection are as follows: Liquid chromatography conditions: Chromatographic column: Fei Nuo Mei Luna omega Polar C18 chromatographic column, 100mm x 2.1mm; Mobile phase A: aqueous solution containing 0.5% formic acid and 2mmol / L ammonium acetate; Mobile phase B: methanol solution containing 0.5% formic acid and 2mmol / L ammonium acetate; Injection volume 10μL, gradient elution, the specific elution conditions are as follows: Mass spectrometry conditions: The mass spectrometer was Thermo scientific TSQ altis, the ion source was electrospray source, the scanning mode was positive and negative ion switching mode, the spray voltage was 3000 V, the cone voltage was 70 V, and the nebulizer flow rate was 60 L / h; Wherein, the mobile phase A is prepared according to the following method: take the mobile phase additive and mix it with 100 times the volume of ultrapure water to obtain the mobile phase A; The mobile phase B is prepared as follows: the mobile phase additive is mixed with 100 times the volume of methanol to obtain the mobile phase B.
Citation Information
Patent Citations
Method and kit for detecting water-soluble vitamins
CN114935619A
Detection kit and detection method for detecting eight metabolites such as homocysteine through high performance liquid chromatography-tandem mass spectrometry
CN116381084A
Method for measuring methylmalonic acid, homocysteine and related metabolites thereof by LC-MS / MS (liquid chromatography-mass spectrometry / mass spectrometry)
CN116818966A
Meanwhile, determining 5apos in the whole blood; kit and method for detecting content of pyridoxal phosphate, betaine and methylmalonic acid
CN117347526A
Compound analysis method for liquorice and liquorice probiotic fermentation preparation
CN117740961A
Cited By
Kit for detecting water-soluble vitamins in serum and preparation and detection method thereof
CN120334425A
Sample diluent for homocysteine detection as well as preparation method and application of sample diluent
CN122524533A
